>Mercado de ingredientes farmacéuticos activos (API) de Asia y el Pacífico, por molécula (molécula pequeña, molécula grande), tipo ( ingredientes farmacéuticos activos innovadores , ingredientes farmacéuticos activos innovadores genéricos), tipo de fabricante (fabricante de API cautivo, fabricante de API comercial), síntesis (ingredientes farmacéuticos activos sintéticos e ingredientes farmacéuticos activos biotecnológicos), síntesis química (acetaminofén, artemisinina, saxagliptina, cloruro de sodio, ibuprofeno, losartán potásico, enoxaparina sódica, rufinamida, naproxeno, tamoxifeno, otros), tipo de fármaco ( medicamentos con receta , de venta libre), uso (clínico, de investigación), potencia (ingredientes farmacéuticos activos de potencia baja a moderada, ingrediente farmacéutico activo de potencia potente a muy alta), aplicación terapéutica (cardiología, sistema nervioso central y neurología, oncología, ortopedia, endocrinología, neumología, gastroenterología, nefrología, Oftalmología, otras aplicaciones terapéuticas), país (Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam, resto de Asia-Pacífico) Tendencias de la industria y pronóstico hasta 2028
Análisis y perspectivas del mercado : mercado de ingredientes farmacéuticos activos (API) de Asia y el Pacífico
Se espera que el mercado de ingredientes farmacéuticos activos (API) gane crecimiento de mercado en el período de pronóstico de 2021 a 2028. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 7,5% en el período de pronóstico de 2021 a 2028 y se espera que alcance los USD 86.222,48 millones para 2028. La creciente prevalencia de diversos trastornos crónicos y el aumento del envejecimiento de la población son los principales impulsores que impulsaron la demanda del mercado de ingredientes farmacéuticos activos (API) en el período de pronóstico.
- En griego, la palabra tradicional para los ingredientes farmacéuticos activos (API) se llama pharmaceutical o pharmakon, que simboliza una sustancia o fármaco mágico. Los ingredientes farmacéuticos activos, como se describen en la ICH Q7, son “cualquier sustancia o combinación de sustancias destinadas a ser utilizadas en la fabricación de un producto farmacéutico que, cuando se utilizan en la producción del fármaco, se convierten en un ingrediente farmacéutico activo. Dichas sustancias se utilizan para proporcionar actividad farmacológica.
Increase in technological advancements will enhance the capabilities and boost the manufacturing skills of the market players that the manufacturers have to provide APIs in bulk and meet the demand of the consumers which can drive the growth of the active pharmaceutical ingredients (API) market. Availability of sub-standard and counterfeit drugs is acting as a restraint for hampering the demand of the active pharmaceutical ingredients (API) market. Rising investment in research regarding the development of APIs will further increase the growth opportunities for the active pharmaceutical ingredients (API) market. Disruption in the supply chain of APIs during COVID-19 acts challenging for the healthcare providers which may challenge the active pharmaceutical ingredients (API) market.
The active pharmaceutical ingredients (API) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an analyst brief, our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Active Pharmaceutical Ingredients (API) Market Scope and Market Size
The active pharmaceutical ingredients (API) market is segmented on the basis of the molecule, type, type of manufacturer, synthesis, chemical synthesis, type of drug, usage, potency and therapeutic application. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of molecule, the active pharmaceutical ingredients (API) market is segmented into small molecule and large molecule. In 2021, small molecule segment is expected to dominate the active pharmaceutical ingredients (API) market due to increasing number of regulatory approval and rising research and development on novel small molecules due to their high penetration power.
- On the basis of type, the active pharmaceutical ingredients (API) market is segmented into innovative active pharmaceutical ingredients and generic active pharmaceutical ingredients. In 2021, innovative active pharmaceutical ingredients segment is expected to dominate the active pharmaceutical ingredients (API) market because of high cost of innovative APIs in comparison to generic APIs and rising FDA approval for the new molecular entities.
- Según el tipo de fabricante, el mercado de ingredientes farmacéuticos activos (API) se segmenta en fabricante de API cautivo y fabricante de API comercial. En 2021, se espera que el segmento de fabricante de API cautivo domine el mercado de ingredientes farmacéuticos activos (API) debido a la enorme inversión de los principales actores del mercado para generar instalaciones de fabricación de alta gama y una fácil disponibilidad de materias primas.
- Sobre la base de la síntesis, el mercado de ingredientes farmacéuticos activos (API) se segmenta en ingredientes farmacéuticos activos sintéticos e ingredientes farmacéuticos activos biotecnológicos. En 2021, se espera que el segmento de ingredientes farmacéuticos activos sintéticos domine el mercado de ingredientes farmacéuticos activos (API) debido al protocolo fácil para la síntesis de moléculas, las pautas regulatorias menos estrictas y, en los próximos años, muchas moléculas sintéticas dejarán de estar patentadas.
- Sobre la base de la síntesis química, el mercado de ingredientes farmacéuticos activos (API) se segmenta en acetaminofeno , artemisinina, saxagliptina, cloruro de sodio , ibuprofeno, losartán potásico, enoxaparina sódica, rufinamida, naproxeno, tamoxifeno y otros. En 2021, se espera que el segmento de saxagliptina domine el mercado de ingredientes farmacéuticos activos (API) debido al alto costo de los API y al aumento de casos de diabetes en todo el mundo.
- Según el tipo de medicamento, el mercado de ingredientes farmacéuticos activos (API) se segmenta en medicamentos con receta y medicamentos de venta libre. En 2021, el segmento de medicamentos con receta domina el mercado de ingredientes farmacéuticos activos (API) debido al alto costo de los medicamentos, lo que aumentará los API y el costo de fabricación de los mismos.
- En función del uso, el mercado de ingredientes farmacéuticos activos (API) se segmenta en clínico y de investigación . En 2021, se espera que el segmento clínico domine el mercado de ingredientes farmacéuticos activos (API) debido al creciente número de enfermedades que requieren un suministro continuo de API y materia prima.
- En función de la potencia, el mercado de ingredientes farmacéuticos activos (API) se segmenta en ingredientes farmacéuticos activos de potencia baja a moderada e ingredientes farmacéuticos activos de potencia potente a muy potente. En 2021, se espera que el segmento de ingredientes farmacéuticos activos de potencia baja a moderada domine el mercado de ingredientes farmacéuticos activos (API) debido a su menor toxicidad y naturaleza menos peligrosa.
- Sobre la base de la aplicación terapéutica, el mercado de ingredientes farmacéuticos activos (API) se segmenta en cardiología, SNC y neurología, oncología , ortopedia, endocrinología, neumología, gastroenterología, nefrología, oftalmología y otras aplicaciones terapéuticas. En 2021, se espera que el segmento de cardiología domine el mercado de ingredientes farmacéuticos activos (API) debido al creciente número de enfermedades cardíacas, como infarto de miocardio, embolia y otras.
Análisis a nivel de país del mercado de ingredientes farmacéuticos activos (API)
Se analiza el mercado de ingredientes farmacéuticos activos (API) y se proporciona información sobre el tamaño del mercado en función del país, la molécula, el tipo, el tipo de fabricante, la síntesis, la síntesis química, el tipo de fármaco, el uso, la potencia y la aplicación terapéutica como se menciona anteriormente.
Los países cubiertos en el informe del mercado de ingredientes farmacéuticos activos (API) de Asia-Pacífico son Japón, China, Australia, India, Corea del Sur, Singapur, Indonesia, Tailandia, Malasia, Filipinas, Vietnam y el resto de Asia-Pacífico.
China domina el mercado de ingredientes farmacéuticos activos (API) de Asia-Pacífico debido a las iniciativas gubernamentales para la producción de API.
La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Los puntos de datos como nuevas ventas, ventas de reemplazo, demografía del país, leyes regulatorias y aranceles de importación y exportación son algunos de los principales indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Asia-Pacífico y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los canales de venta se consideran al proporcionar un análisis de pronóstico de los datos del país.
La creciente prevalencia de diversos trastornos crónicos está impulsando el crecimiento del mercado de ingredientes farmacéuticos activos (API)
El mercado de ingredientes farmacéuticos activos (API) también le proporciona un análisis detallado del mercado para cada país: el crecimiento de la industria de ingredientes farmacéuticos activos (API) con las ventas de medicamentos con ingredientes farmacéuticos activos (API), el impacto del avance en la tecnología de ingredientes farmacéuticos activos (API) y los cambios en los escenarios regulatorios con su apoyo al mercado de ingredientes farmacéuticos activos (API). Los datos están disponibles para el período histórico de 2010 a 2019.
Análisis del panorama competitivo y de la cuota de mercado de los ingredientes farmacéuticos activos (API)
El panorama competitivo del mercado de ingredientes farmacéuticos activos (API) proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, los sitios e instalaciones de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, los procesos de prueba de productos, las aprobaciones de productos, las patentes, la amplitud y amplitud de los productos, el dominio de las aplicaciones y la curva de la línea de vida de la tecnología. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de la empresa relacionado con el mercado de ingredientes farmacéuticos activos (API).
Las principales empresas que se dedican a los ingredientes farmacéuticos activos (API) son Dr. Reddy's Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Pfizer Inc., Sanofi, GlaxoSmithKline plc., Aarti Industries Limited, Recipharm AB, Jubilant Pharmova Limited, LUPIN, Aurobindo Pharma, AbbVie Inc., AstraZeneca, Alkem Labs, Albemarle Corporation, Saneca Pharmaceuticals, Unichem Laboratories, Neuland Laboratories Ltd., Divi's Laboratories Limited., HIKAL Ltd., Viatris Inc., Merck KGaA, Novo Nordisk A/S, Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., BASF SE, Piramal Pharma Solutions, entre otras. Los analistas de DBMR comprenden las fortalezas competitivas y brindan un análisis competitivo para cada competidor por separado.
Muchos lanzamientos y acuerdos de productos también son iniciados por empresas de todo el mundo, lo que también está acelerando el mercado de ingredientes farmacéuticos activos (API).
Por ejemplo,
- En diciembre de 2019, AbbVie Inc. colaboró con Scripps Research para impulsar la investigación de nuevos fármacos dirigidos a una variedad de enfermedades, incluidas las áreas de oncología e inmunología, entre otras. Según el acuerdo de colaboración, Scripps Research llevará a cabo las actividades de investigación preclínica para el desarrollo de nuevas terapias. Esta colaboración ayudó a la empresa a avanzar en sus nuevos medicamentos para pacientes, lo que en última instancia ha impulsado los ingresos de la empresa.
La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando el mercado de la empresa en el mercado de ingredientes farmacéuticos activos (API), lo que también brinda el beneficio para que la organización mejore su oferta de ingredientes farmacéuticos activos (API).
SKU-
Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo
- Panel de análisis de datos interactivo
- Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
- Acceso de analista de investigación para personalización y consultas
- Análisis de la competencia con panel interactivo
- Últimas noticias, actualizaciones y análisis de tendencias
- Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Tabla de contenido
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 MOLECULE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET TYPE OF MANUFACTURER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHT
4.1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COUNTRIES WITH DATA OF IMPORTS AND EXPORTS
4.2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE ORIGIN COUNTRY OF THE IMPORTS
4.3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS: COLOMBIA DATA OF THE IMPORTS AND EXPORTS BY MOLECULES IN VALUES AND VOLUMES
5 PIPELINE ANALYSIS
6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: REGULATORY FRAMEWORK
6.1 CURRENT GOODS MANUFACTURING PRACTICES
6.2 REGULATORY REQUIREMENTS FOR REGISTRATION OF API IN THE U.S. AND EU
6.3 REGISTRATION OF API IN THE U.S.
6.4 REGISTRATION OF API IN EUROPE
6.5 REGULATORY REQUIREMENTS IN INDIA
6.6 REGULATORY FRAMEWORK IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASING PREVALENCE OF VARIOUS CHRONIC DISORDERS
7.1.2 INCREASE IN AGING POPULATION
7.1.3 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURING
7.1.4 INCREASING DISEASE AWARENESS AND EDUCATION
7.1.5 PATENT EXPIRY OF BRANDED ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.2 RESTRAINTS
7.2.1 AVAILABILITY OF SUB-STANDARD AND COUNTERFEIT DRUGS
7.2.2 HIGH MANUFACTURING COST
7.2.3 ADVERSE HEALTH EFFECTS OF EXPOSURE TO ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.3 OPPORTUNITIES
7.3.1 COLLABORATION AND ACQUISITION AMONG THE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
7.3.2 INCREASING HEALTHCARE EXPENDITURE
7.3.3 RISING INVESTMENT IN RESEARCH REGARDING THE DEVELOPMENT OF ACTIVE PHARMACEUTICAL INGREDIENTS (API)
7.3.4 SOARING NUMBER OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) MANUFACTURERS
7.4 CHALLENGES
7.4.1 DISRUPTION IN THE SUPPLY CHAIN OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) DURING COVID-19
7.4.2 LACK OF WORKFORCE IN PHARMA INDUSTRIES
7.4.3 PRODUCT RECALLS
8 IMPACT OF COVID 19 PANDEMIC ON THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
8.1 PRICE IMPACT
8.2 IMPACT ON SUPPLY CHAIN
8.3 IMPACT ON DEMAND
8.4 STRATEGIC DECISIONS FOR MANUFACTURERS
8.5 CONCLUSION
9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE
9.1 OVERVIEW
9.2 SMALL MOLECULE
9.3 LARGE MOLECULE
10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE
10.1 OVERVIEW
10.2 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
10.3 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER
11.1 OVERVIEW
11.2 CAPTIVE API MANUFACTURERS
11.3 MERCHANT API MANUFACTURERS
11.3.1 TYPE
11.3.1.1 Merchant Innovative API Manufacturers
11.3.1.2 Merchant Generic API Manufacturers
11.3.2 TYPE OF SYNTHESIS
11.3.2.1 Merchant Synthetic API Manufacturers
11.3.2.2 Merchant Biotech API Manufacturers
12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS
12.1 OVERVIEW
12.2 SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT
12.2.1 INNOVATIVE SYNTHETIC APIS
12.2.2 GENERIC SYNTHETIC APIS
12.3 BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT
12.3.1 TYPE
12.3.1.1 Innovative Biotech APIs
12.3.1.2 Generic Biotech APIs
12.3.2 PRODUCT
12.3.2.1 Monoclonal Antibodies
12.3.2.2 Adalimumab
12.3.2.3 Ustekinumab
12.3.2.4 Secukinumab
12.3.2.5 Cetuximab
12.3.2.6 Daclizumab
12.3.2.7 Omalizumab
12.3.2.8 Vedolizumab
12.3.2.9 Abciximab
12.3.2.10 Efalizumab
12.3.2.11 Others
12.3.2.2 Cytokines
12.3.2.2.1 Interleukin-2
12.3.2.2.2 Interferon Beta-1A
12.3.2.2.3 Interleukin-10
12.3.2.2.4 Interleukin-9
12.3.2.2.5 Erythropoietin
12.3.2.2.6 Others
12.3.2.3 Hormones & Growth Factors
12.3.2.4 Blood Factors
12.3.2.5 Recombinant Vaccines
12.3.2.6 Therapeutic Enzymes
12.3.3 EXPRESSION SYSTEM
12.3.3.1 Mammalian Expression System
12.3.3.2 Yeast Expression System
12.3.3.3 Microbial Expression System
12.3.3.4 Insect Expression System
12.3.3.5 Others Expression System
13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS
13.1 OVERVIEW
13.2 SAXAGLIPTIN
13.3 ENOXAPARIN SODIUM
13.4 RUFINAMIDE
13.5 TAMOXIFEN
13.6 ARTEMISININ
13.7 LOSARTAN POTASSIUM
13.8 NAPROXEN
13.9 IBUPROFEN
13.1 ACETAMINOPHEN
13.11 SODIUM CHLORIDE
13.12 OTHERS
14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG
14.1 OVERVIEW
14.2 PRESCRIPTION DRUGS
14.3 OVER-THE-COUNTER
15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE
15.1 OVERVIEW
15.2 CLINICAL
15.3 RESEARCH
16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY
16.1 OVERVIEW
16.2 LOW-TO-MODERATE POTENT ACTIVE PHARMACEUTICAL INGREDIENT
16.3 POTENT-TO-HIGHLY POTENT ACTIVE PHARMACEUTICAL INGREDIENT
17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION
17.1 OVERVIEW
17.2 CARDIOLOGY
17.2.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.2.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.3 CNS & NEUROLOGY
17.3.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.3.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.4 ONCOLOGY
17.4.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.4.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.5 GASTROENTEROLOGY
17.5.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.5.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.6 PULMONOLOGY
17.6.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.6.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.7 ENDOCRINOLOGY
17.7.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.7.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.8 NEPHROLOGY
17.8.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.8.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.9 ORTHOPEDIC
17.9.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.9.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.1 OPHTHALMOLOGY
17.10.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.10.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
17.11 OTHERS
17.11.1 INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT
17.11.2 GENERIC ACTIVE PHARMACEUTICAL INGREDIENT
18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS MARKET BY REGION
18.1 ASIA-PACIFIC
18.1.1 CHINA
18.1.2 INDIA
18.1.3 JAPAN
18.1.4 AUSTRALIA
18.1.5 SOUTH KOREA
18.1.6 SINGAPORE
18.1.7 MALAYSIA
18.1.8 THAILAND
18.1.9 INDONESIA
18.1.10 PHILIPPINES
18.1.11 VIETNAM
18.1.12 REST OF ASIA-PACIFIC
19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, COMPANY LANDSCAPE
19.1 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
20 SWOT ANALYSIS
21 COMPANY PROFILE
21.1 TEVA PHARMECEUTICALS INDUSTRIES LTD.
21.1.1 COMPANY SNAPSHOT
21.1.2 RECENT FINANCIALS
21.1.3 COMPANY SHARE ANALYSIS
21.1.4 PRODUCT PORTFOLIO
21.1.5 RECENT DEVELOPMENT
21.2 PFIZER, INC.
21.2.1 COMPANY SNAPSHOT
21.2.2 REVENUE ANALYSIS
21.2.3 COMPANY SHARE ANALYSIS
21.2.4 PRODUCT PORTFOLIO
21.2.5 RECENT DEVELOPMENTS
21.3 SANOFI
21.3.1 COMPANY SNAPSHOT
21.3.2 REVENUE ANALYSIS
21.3.3 COMPANY SHARE ANALYSIS
21.3.4 PRODUCT PORTFOLIO
21.3.5 RECENT DEVELOPMENTS
21.4 MERCK KGAA
21.4.1 COMPANY SNAPSHOT
21.4.2 REVENUE ANALYSIS
21.4.3 COMPANY SHARE ANALYSIS
21.4.4 PRODUCT PORTFOLIO
21.4.5 RECENT DEVELOPMENT
21.5 SANDOZ INTERNATIONAL GMBH (A SUBSIDIARY OF NOVARTIS AG)
21.5.1 COMPANY SNAPSHOT
21.5.2 REVENUE ANALYSIS
21.5.3 PRODUCT PORTFOLIO
21.5.4 RECENT DEVELOPMENT
21.6 AUROBINDO PHARMA
21.6.1 COMPANY SNAPSHOT
21.6.2 REVENUE ANALYSIS
21.6.3 PRODUCT PORTFOLIO
21.6.4 RECENT DEVELOPMENT
21.7 ALBEMARLE CORPORATION
21.7.1 COMPANY SNAPSHOT
21.7.2 REVENUE ANALYSIS
21.7.3 PRODUCT PORTFOLIO
21.7.4 RECENT DEVELOPMENTS
21.8 ASTRAZENECA
21.8.1 COMPANY SNAPSHOT
21.8.2 REVENUE ANALYSIS
21.8.3 PRODUCT PORTFOLIO
21.8.4 RECENT DEVELOPMENT
21.9 DIVI’S LABORATORIES LIMITED
21.9.1 COMPANY SNAPSHOT
21.9.2 REVENUE ANALYSIS
21.9.3 PRODUCT PORTFOLIO
21.9.4 RECENT DEVELOPMENTS
21.1 DR. REDDY’S LABORATORY LTD.
21.10.1 COMPANY SNAPSHOT
21.10.2 RECENT FINANCIALS
21.10.3 PRODUCT PORTFOLIO
21.10.4 RECENT DEVELOPMENT
21.11 PIRAMAL PHARMA SOLUTIONS
21.11.1 COMPANY SNAPSHOT
21.11.2 PRODUCT PORTFOLIO
21.11.3 RECENT DEVELOPMENTS
21.12 AARTI INDUSTRIES LIMITED
21.12.1 COMPANY SNAPSHOT
21.12.2 REVENUE ANALYSIS
21.12.3 PRODUCT PORTFOLIO
21.12.4 RECENT DEVELOPMENT
21.13 ABBVIE INC
21.13.1 COMPANY SNAPSHOT
21.13.2 REVENUE ANALYSIS
21.13.3 PRODUCT PORTFOLIO
21.13.4 RECENT DEVELOPMENTS
21.14 ALKEM LABS
21.14.1 COMPANY SNAPSHOT
21.14.2 REVENUE ANALYSIS
21.14.3 PRODUCT PORTFOLIO
21.14.4 RECENT DEVELOPMENTS
21.15 ALEMBIC PHARMACEUTICALS LIMITED
21.15.1 COMPANY SNAPSHOT
21.15.2 REVENUE ANALYSIS
21.15.3 PRODUCT PORTFOLIO
21.15.4 RECENT DEVELOPMENTS
21.16 BASF SE
21.16.1 COMPANY SNAPSHOT
21.16.2 RECENT FINANCIALS
21.16.3 PRODUCT PORTFOLIO
21.16.4 RECENT DEVELOPMENT
21.17 CIPLA INC.
21.17.1 COMPANY SNAPSHOT
21.17.2 RECENT FINANCIALS
21.17.3 PRODUCT PORTFOLIO
21.17.4 RECENT DEVELOPMENTS
21.18 CORDENPHARMA INTERNATIONAL
21.18.1 COMPANY SNAPSHOT
21.18.2 PRODUCT PORTFOLIO
21.18.3 RECENT DEVELOPMENTS
21.19 GLAXOSMITHKLINE PLC
21.19.1 COMPANY SNAPSHOT
21.19.2 REVENUE FINANCIALS
21.19.3 PRODUCT PORTFOLIO
21.19.4 RECENT DEVELOPMENT
21.2 HIKAL LTD.
21.20.1 COMPANY SNAPSHOT
21.20.2 REVENUE ANALYSIS
21.20.3 PRODUCT PORTFOLIO
21.20.4 RECENT DEVELOPMENTS
21.21 JUBILANT LIFE SCIENCES LIMITED
21.21.1 COMPANY SNAPSHOT
21.21.2 REVENUE ANALYSIS
21.21.3 PRODUCT PORTFOLIO
21.21.4 RECENT DEVELOPMENT
21.22 LUPIN
21.22.1 COMPANY SNAPSHOT
21.22.2 REVENUE ANALYSIS
21.22.3 PRODUCT PORTFOLIO
21.22.4 RECENT DEVELOPMENTS
21.23 MINAKIM
21.23.1 COMPANY SNAPSHOT
21.23.2 PRODUCT PORTFOLIO
21.23.3 RECENT DEVELOPMENTS
21.24 NEULAND LABORATORIES LTD.
21.24.1 COMPANY SNAPSHOT
21.24.2 REVENUE ANALYSIS
21.24.3 PRODUCT PORTFOLIO
21.24.4 RECENT DEVELOPMENTS
21.25 NOVO NORDISK A/S
21.25.1 COMPANY SNAPSHOT
21.25.2 REVENUE ANALYSIS
21.25.3 PRODUCT PORTFOLIO
21.25.4 RECENT DEVELOPMENT
21.26 RECIPHARM AB
21.26.1 COMPANY SNAPSHOT
21.26.2 REVENUE ANALYSIS
21.26.3 PRODUCT PORTFOLIO
21.26.4 RECENT DEVELOPMENTS
21.27 SANECA PHARMACEUTICALS
21.27.1 COMPANY SNAPSHOT
21.27.2 PRODUCT PORTFOLIO
21.27.3 RECENT DEVELOPMENTS
21.28 SUN PHARMACEUTICAL INDUSTRIES LTD.
21.28.1 COMPANY SNAPSHOT
21.28.2 REVENUE ANALYSIS
21.28.3 PRODUCT PORTFOLIO
21.28.4 RECENT DEVELOPMENTS
21.29 UNICHEM LABORATORIES
21.29.1 COMPANY SNAPSHOT
21.29.2 REVENUE ANALYSIS
21.29.3 PRODUCT PORTFOLIO
21.29.4 RECENT DEVELOPMENTS
21.3 VIATRIS INC.
21.30.1 COMPANY SNAPSHOT
21.30.2 PRODUCT PORTFOLIO
21.30.3 RECENT DEVELOPMENTS
22 QUESTIONNAIRE
23 RELATED REPORTS
Lista de Tablas
TABLE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, PIPELINE ANALYSIS
TABLE 2 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE REGISTRATION PROCESS
TABLE 3 DIFFERENCE BETWEEN THE U.S. AND EU FOR THE ADMINISTRATIVE REQUIREMENTS
TABLE 4 AGE DISTRIBUTION OF THE U.K. POPULATION (FROM 1976 TO 2046)
TABLE 5 WORLD –WIDE IMPACT OF COVID-19 ON THE PHARMACEUTICAL SECTOR
TABLE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 7 ASIA-PACIFIC SMALL MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 8 ASIA-PACIFIC LARGE MOLECULE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 10 ASIA-PACIFIC INNOVATIVE ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 11 ASIA-PACIFIC GENERIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)
TABLE 13 ASIA-PACIFIC CAPTIVE API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 14 ASIA-PACIFIC MERCHANT API MANUFACTURER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET , BY REGION, 2017-2028 (USD MILLION)
TABLE 15 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 16 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 18 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 19 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 20 ASIA-PACIFIC BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 21 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 22 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 23 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 24 ASIA-PACIFIC CYTOKINESPRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 25 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGREDIENT INACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (USD MILLION)
TABLE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (UNITS)
TABLE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2019-2028 (ASP)
TABLE 29 ASIA-PACIFIC SAXAGLIPTIN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, REGION, 2017-2028 (USD MILLION)
TABLE 30 ASIA-PACIFIC ENOXAPARIN SODIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 31 ASIA-PACIFIC RUFINAMIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 32 ASIA-PACIFIC TAMOXIFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 33 ASIA-PACIFIC ARTEMISININ IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 34 ASIA-PACIFIC LOSARTAN POTASSIUM IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 35 ASIA-PACIFIC NAPROXEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 36 ASIA-PACIFIC IBUPROFEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 37 ASIA-PACIFIC ACETAMINOPHEN IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 38 ASIA-PACIFIC SODIUM CHLORIDE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 39 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 40 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2019-2028 (USD MILLION)
TABLE 41 ASIA-PACIFIC PRESCRIPTION DRUGS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 42 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 43 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 44 ASIA-PACIFIC CLINICAL IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 45 ASIA-PACIFIC OVER-THE-COUNTER IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 46 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 47 ASIA-PACIFIC LOW-TO-MODERATE IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 48 ASIA-PACIFIC POTENT-TO-HIGHLY POTENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 49 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 50 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 51 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 52 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 53 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 54 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 55 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 56 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 57 ASIA-PACIFIC GASTROENTEROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 58 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 59 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 60 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 61 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 62 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 63 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 64 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 65 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 66 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 67 ASIA-PACIFIC OPHTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 68 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 69 ASIA-PACIFIC OTHERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 70 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY COUNTRY, 2018-2028 (USD MILLION)
TABLE 71 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 72 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 73 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 74 ASIA-PACIFIC TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 75 ASIA-PACIFIC TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 76 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 77 ASIA-PACIFIC SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 78 ASIA-PACIFIC TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 79 ASIA-PACIFIC PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 80 ASIA-PACIFIC MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 81 ASIA-PACIFIC CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 82 ASIA-PACIFIC EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 83 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 84 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 85 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 86 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 87 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 88 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 89 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 90 ASIA-PACIFIC CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 91 ASIA-PACIFIC CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 92 ASIA-PACIFIC ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 93 ASIA-PACIFIC GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 94 ASIA-PACIFIC PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 95 ASIA-PACIFIC ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 96 ASIA-PACIFIC NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 97 ASIA-PACIFIC ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 98 ASIA-PACIFIC OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 99 ASIA-PACIFIC OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 100 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 101 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 102 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 103 CHINA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 104 CHINA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 105 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 106 CHINA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 107 CHINA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 108 CHINA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 109 CHINA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 110 CHINA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 111 CHINA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 112 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 113 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 114 UDI ARABIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 115 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 116 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 117 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 118 CHINA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 119 CHINA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 120 CHINA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 121 CHINA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 122 CHINA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 123 CHINA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 124 CHINA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 125 CHINA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 126 CHINA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 127 CHINA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 128 CHINA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 129 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 130 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 131 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 132 INDIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 133 INDIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 134 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 135 INDIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 136 INDIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 137 INDIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 138 INDIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 139 INDIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 140 INDIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 141 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 142 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 143 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 144 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 145 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 146 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 147 INDIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 148 INDIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 149 INDIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 150 INDIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 151 INDIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 152 INDIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 153 INDIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 154 INDIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 155 INDIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 156 INDIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 157 INDIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 158 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 159 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 160 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 161 JAPAN TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 162 JAPAN TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 163 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 164 JAPAN SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 165 JAPAN TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 166 JAPAN PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 167 JAPAN MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 168 JAPAN CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 169 JAPAN EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 170 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 171 AE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 172 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 173 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 174 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 175 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 176 JAPAN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 177 JAPAN CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 178 JAPAN CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 179 JAPAN ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 180 JAPAN GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 181 JAPAN PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 182 JAPAN ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 183 JAPAN NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 184 JAPAN ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 185 JAPAN OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 186 JAPAN OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 187 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 188 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 189 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 190 AUSTRALIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 191 AUSTRALIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 192 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 193 AUSTRALIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 194 AUSTRALIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 195 AUSTRALIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 196 AUSTRALIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 197 AUSTRALIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 198 AUSTRALIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 199 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 200 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 201 ISREAL ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 202 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 203 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 204 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 205 AUSTRALIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 206 AUSTRALIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 207 AUSTRALIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 208 AUSTRALIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 209 AUSTRALIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 210 AUSTRALIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 211 AUSTRALIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 212 AUSTRALIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 213 AUSTRALIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 214 AUSTRALIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 215 AUSTRALIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 216 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 217 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 218 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 219 SOUTH KOREA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 220 SOUTH KOREA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 221 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 222 SOUTH KOREA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 223 SOUTH KOREA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 224 SOUTH KOREA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 225 SOUTH KOREA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 226 SOUTH KOREA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 227 SOUTH KOREA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 228 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 229 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 230 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 231 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 232 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 233 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 234 SOUTH KOREA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 235 SOUTH KOREA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 236 SOUTH KOREA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 237 SOUTH KOREA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 238 SOUTH KOREA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 239 SOUTH KOREA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 240 SOUTH KOREA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 241 SOUTH KOREA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 242 SOUTH KOREA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 243 SOUTH KOREA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 244 SOUTH KOREA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 245 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 246 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 247 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 248 SINGAPORE TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 249 SINGAPORE TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 250 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 251 SINGAPORE SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 252 SINGAPORE TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 253 SINGAPORE PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 254 SINGAPORE MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 255 SINGAPORE CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 256 SINGAPORE EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 257 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 258 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 259 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 260 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 261 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 262 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 263 SINGAPORE ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 264 SINGAPORE CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 265 SINGAPORE CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 266 SINGAPORE ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 267 SINGAPORE GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 268 SINGAPORE PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 269 SINGAPORE ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 270 SINGAPORE NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 271 SINGAPORE ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 272 SINGAPORE OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 273 SINGAPORE OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 274 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 275 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 276 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 277 MALAYSIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 278 MALAYSIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 279 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 280 MALAYSIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 281 MALAYSIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 282 MALAYSIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 283 MALAYSIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 284 MALAYSIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 285 MALAYSIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 286 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 287 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 288 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 289 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 290 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 291 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 292 MALAYSIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 293 MALAYSIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 294 MALAYSIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 295 MALAYSIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 296 MALAYSIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 297 MALAYSIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 298 MALAYSIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 299 MALAYSIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 300 MALAYSIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 301 MALAYSIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 302 MALAYSIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 303 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 304 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 305 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 306 THAILAND TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 307 THAILAND TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 308 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 309 THAILAND SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 310 THAILAND TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 311 THAILAND PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 312 THAILAND MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 313 THAILAND CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 314 THAILAND EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 315 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 316 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 317 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 318 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 319 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 320 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 321 THAILAND ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 322 THAILAND CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 323 THAILAND CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 324 THAILAND ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 325 THAILAND GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 326 THAILAND PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 327 THAILAND ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 328 THAILAND NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 329 THAILAND ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 330 THAILAND OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 331 THAILAND OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 332 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 333 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 334 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 335 INDONESIA TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 336 INDONESIA TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 337 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 338 INDONESIA SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 339 INDONESIA TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 340 INDONESIA PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 341 INDONESIA MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 342 INDONESIA CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 343 INDONESIA EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 344 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 345 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 346 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 347 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 348 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 349 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 350 INDONESIA ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 351 INDONESIA CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 352 INDONESIA CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 353 INDONESIA ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 354 INDONESIA GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 355 INDONESIA PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 356 INDONESIA ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 357 INDONESIA NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 358 INDONESIA ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 359 INDONESIA OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 360 INDONESIA OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 361 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 362 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 363 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 364 PHILIPPINES TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 365 PHILIPPINES TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 366 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 367 PHILIPPINES SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 368 PHILIPPINES TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 369 PHILIPPINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 370 PHILIPPINES MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 371 PHILIPPINES CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 372 PHILIPPINES EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 373 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 374 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 375 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 376 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 377 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 378 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 379 PHILIPPINES ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 380 PHILIPPINES CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 381 PHILIPPINES CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 382 PHILIPPINES ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 383 PHILIPPINES GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 384 PHILIPPINES PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 385 PHILIPPINES ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 386 PHILIPPINES NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 387 PHILIPPINES ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 388 PHILIPPINES OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 389 PHILIPPINES OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 390 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
TABLE 391 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE, 2017-2028 (USD MILLION)
TABLE 392 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 393 VIETNAM TYPE IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER, 2017-2028 (USD MILLION)
TABLE 394 VIETNAM TYPE OF SYNTHESIS IN MERCHANT API MANUFACTURERS IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF MANUFACTURER,, 2017-2028 (USD MILLION)
TABLE 395 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 396 VIETNAM SYNTHETIC ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 397 VIETNAM TYPE IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 398 VIETNAM PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 399 VIETNAM MONOCLONAL ANTIBODIES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS,, 2017-2028 (USD MILLION)
TABLE 400 VIETNAM CYTOKINES PRODUCT IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 401 VIETNAM EXPRESSION SYSTEM IN BIOTECH ACTIVE PHARMACEUTICAL INGEDIENT IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 402 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
TABLE 403 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (UNITS)
TABLE 404 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY CHEMICAL SYNTHESIS, 2017-2028 (ASP)
TABLE 405 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY TYPE OF DRUG, 2017-2028 (USD MILLION)
TABLE 406 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY USAGE, 2017-2028 (USD MILLION)
TABLE 407 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY POTENCY, 2017-2028 (USD MILLION)
TABLE 408 VIETNAM ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 409 VIETNAM CARDIOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 410 VIETNAM CNS & NEUROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 411 VIETNAM ONCOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 412 VIETNAM GASTROENTROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 413 VIETNAM PULMONOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 414 VIETNAM ENDOCRINOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 415 VIETNAM NEPHROLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 416 VIETNAM ORTHOPEDIC IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 417 VIETNAM OPTHALMOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 418 VIETNAM OTHER THERAPEUTIC APPLICATION IN ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
TABLE 419 REST OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET, BY MOLECULE, 2017-2028 (USD MILLION)
Lista de figuras
FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DATA TRIANGULATION
FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DROC ANALYSIS
FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: ASIA-PACIFIC VS REGIONAL MARKET ANALYSIS
FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MULTIVARIATE MODELLING
FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: DBMR MARKET POSITION GRID
FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: MARKET TYPE OF MANUFACTURER COVERAGE GRID
FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SEGMENTATION
FIGURE 12 UTILIZATION OF ADVANCED TECHNOLOGY IN ACTIVE PHARMACEUTICAL INGREDIENTS MANUFACTURING IS DRIVING THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 SMALL MOLECULE SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET
FIGURE 15 NUMBER OF PERSONS AGED 60 YEARS ACROSS SEVERAL REGIONS IN 2017 AND 2050
FIGURE 16 HEALTHCARE EXPENDITURE PER CAPITA
FIGURE 17 SHARE OF API MARKET OCCUPIED IN ASIA
FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2021
FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, 2017-2028 (USD MILLION)
FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, CAGR (2021-2028)
FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE, LIFELINE CURVE
FIGURE 1 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2021
FIGURE 2 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, 2017-2028 (USD MILLION)
FIGURE 3 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 4 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE, LIFELINE CURVE
FIGURE 5 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2021
FIGURE 6 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, 2017-2028 (USD MILLION)
FIGURE 7 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, CAGR (2021-2028)
FIGURE 8 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF MANUFACTURERS, LIFELINE CURVE
FIGURE 9 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2021
FIGURE 10 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, 2017-2028 (USD MILLION)
FIGURE 11 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, CAGR (2021-2028)
FIGURE 12 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY SYNTHESIS, LIFELINE CURVE
FIGURE 13 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2021
FIGURE 14 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, 2017-2028 (USD MILLION)
FIGURE 15 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, CAGR (2021-2028)
FIGURE 16 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY CHEMICAL SYNTHESIS, LIFELINE CURVE
FIGURE 17 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2021
FIGURE 18 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, 2017-2028 (USD MILLION)
FIGURE 19 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, CAGR (2021-2028)
FIGURE 20 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY TYPE OF DRUG, LIFELINE CURVE
FIGURE 21 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2021
FIGURE 22 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, 2017-2028 (USD MILLION)
FIGURE 23 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, CAGR (2021-2028)
FIGURE 24 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY USAGE, LIFELINE CURVE
FIGURE 25 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2021
FIGURE 26 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, 2017-2028 (USD MILLION)
FIGURE 27 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, CAGR (2021-2028)
FIGURE 28 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY POTENCY, LIFELINE CURVE
FIGURE 29 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2021
FIGURE 30 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, 2017-2028 (USD MILLION)
FIGURE 31 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, CAGR (2021-2028)
FIGURE 32 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE
FIGURE 33 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: SNAPSHOT (2020)
FIGURE 34 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020)
FIGURE 35 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2021 & 2028)
FIGURE 36 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY COUNTRY (2020 & 2028)
FIGURE 37 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: BY MOLECULE (2021-2028)
FIGURE 38 ASIA-PACIFIC ACTIVE PHARMACEUTICAL INGREDIENTS (API) MARKET: COMPANY SHARE 2020 (%)
Metodología de investigación
La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.
La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.
Personalización disponible
Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.
